Israel China Biotechnology (ICB) Ltd
Silver Castle Holdings Ltd operates as a healthcare investment company. It invests in companies in the biomedical field in Israel. The company was formerly known as Israel China Biotechnology (ICB) Ltd and changed its name to Silver Castle Holdings Ltd in February 2022. Silver Castle Holdings Ltd was founded in 2000 and is based in Tel Aviv, Israel.
Israel China Biotechnology (ICB) Ltd (ICB) - Total Assets
Latest total assets as of June 2021: ILA6.66 Million ILA
Based on the latest financial reports, Israel China Biotechnology (ICB) Ltd (ICB) holds total assets worth ILA6.66 Million ILA as of June 2021.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Israel China Biotechnology (ICB) Ltd - Total Assets Trend (2015–2020)
This chart illustrates how Israel China Biotechnology (ICB) Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Israel China Biotechnology (ICB) Ltd - Asset Composition Analysis
Current Asset Composition (December 2020)
Israel China Biotechnology (ICB) Ltd's total assets of ILA6.66 Million consist of 25.5% current assets and 74.5% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 24.8% |
| Accounts Receivable | ILA47.00K | 0.6% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA2.01 Million | 24.1% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2015–2020)
This chart illustrates how Israel China Biotechnology (ICB) Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Israel China Biotechnology (ICB) Ltd's current assets represent 25.5% of total assets in 2020, a decrease from 92.2% in 2015.
- Cash Position: Cash and equivalents constituted 24.8% of total assets in 2020, down from 90.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 24.1% of total assets.
Israel China Biotechnology (ICB) Ltd Competitors by Total Assets
Key competitors of Israel China Biotechnology (ICB) Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Q Capital Partners Co. Ltd
KQ:016600
|
Korea | ₩184.22 Billion |
|
SBI Investment KOREA Co. Ltd
KQ:019550
|
Korea | ₩145.68 Billion |
|
Leaders Technology Investment Co. Ltd
KQ:019570
|
Korea | ₩59.66 Billion |
|
Aju IB Investment Co. Ltd
KQ:027360
|
Korea | ₩336.45 Billion |
|
Daesung Private Equity Inc
KQ:027830
|
Korea | ₩98.07 Billion |
|
ISE Commerce Company Limited
KQ:069920
|
Korea | ₩91.38 Billion |
|
EBEST Investment & Securities Co. Ltd
KQ:078020
|
Korea | ₩9.66 Trillion |
|
Mirae Asset Venture Investment Co. Ltd
KQ:100790
|
Korea | ₩1.08 Trillion |
Israel China Biotechnology (ICB) Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Israel China Biotechnology (ICB) Ltd generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Israel China Biotechnology (ICB) Ltd is currently not profitable relative to its asset base.
Israel China Biotechnology (ICB) Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.29 | 0.65 | 4.80 |
| Quick Ratio | 0.29 | 0.61 | 4.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA-2.27 Million | ILA -1.21 Million | ILA 4.58 Million |
Israel China Biotechnology (ICB) Ltd - Advanced Valuation Insights
This section examines the relationship between Israel China Biotechnology (ICB) Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.89 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -27.9% |
| Total Assets | ILA8.34 Million |
| Market Capitalization | $52.21K USD |
Valuation Analysis
Below Book Valuation: The market values Israel China Biotechnology (ICB) Ltd's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Israel China Biotechnology (ICB) Ltd's assets decreased by 27.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Israel China Biotechnology (ICB) Ltd (2015–2020)
The table below shows the annual total assets of Israel China Biotechnology (ICB) Ltd from 2015 to 2020.
| Year | Total Assets | Change |
|---|---|---|
| 2020-12-31 | ILA8.34 Million | -27.87% |
| 2019-12-31 | ILA11.57 Million | +17.12% |
| 2018-12-31 | ILA9.88 Million | +736.16% |
| 2017-12-31 | ILA1.18 Million | -70.89% |
| 2016-12-31 | ILA4.06 Million | -50.38% |
| 2015-12-31 | ILA8.18 Million | -- |